In MRI substudy, trevogrumab prevented 70% of semaglutide-linked muscle loss
In a pre-specified subgroup meeting the low lean mass definition for sarcopenia, Regeneron Pharmaceuticals said semaglutide caused greater lean mass loss and trevogrumab more preservation.
GetSignal Regeneron Pharmaceuticals REGN
Regeneron Pharmaceuticals announced new Phase 2 COURAGE trial results for trevogrumab in people with obesity on GLP-1 receptor agonist weight loss on October 1, 2026.
In a predefined MRI substudy, the company said trevogrumab prevented 70% of muscle loss associated with semaglutide treatment. The findings were presented at the European Association for the Study of Diabetes Annual Meeting and are in press with The Lancet.
Key facts
- Trial
- Phase 2 COURAGE
- Muscle loss prevented
- 70% in a predefined MRI substudy, with semaglutide
- Announced
- October 1, 2026
Source: The company's release on GlobeNewswire, October 1, 2026.
Written by GetSignal with AI from the company's press release.
Not investment advice.
